Citation Impact
Citing Papers
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
2001 StandoutScience
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
Antifungal Prophylaxis to Prevent Invasive Mycoses Among Bone Marrow Transplantation Recipients
1998
Post-remission therapy for acute myeloid leukemia
2014
Gut microbiota functions: metabolism of nutrients and other food components
2017 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The β-Thalassemias
1999 Standout
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
2015
New treatment for acute myelogenous leukemia
2014
The past and future of CD33 as therapeutic target in acute myeloid leukemia
2014
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Cancer stem cells revisited
2017 Standout
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
2014
Targeting apoptosis in cancer therapy
2020 Standout
Antibody–drug conjugates: current status and future directions
2013
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
2012
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Gut flora in health and disease
2003 Standout
PI3K/Akt signalling pathway and cancer
2003 Standout
Molecular signals in anti-apoptotic survival pathways
2001
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Periodontitis: a polymicrobial disruption of host homeostasis
2010 Standout
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
2000 StandoutNobel
Global epidemiology of haemoglobin disorders and derived service indicators
2008 Standout
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies
2011
The gut microbiota shapes intestinal immune responses during health and disease
2009 Standout
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
2014
Gut Microbiota in Health and Disease
2010 Standout
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
2010
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
2014
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
2013
Acute Myeloid Leukemia
2015 Standout
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
2015
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Role of gastrointestinal microbiota in fish
2010 Standout
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)
2003
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
2013
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
2009
Current and Emerging Azole Antifungal Agents
1999 Standout
Antifungal prophylaxis during neutropenia and immunodeficiency
1997
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysis
2013
Commensal Host-Bacterial Relationships in the Gut
2001 StandoutScience
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
2007 Standout
A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem
1999
Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax
1996
Toward the potential cure of leukemias in the next decade
2018
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
2005 Standout
Gemtuzumab ozogamicin for acute myeloid leukemia
2017
Cancer treatment and survivorship statistics, 2016
2016 Standout
Antibody therapy for acute myeloid leukaemia
2013
How I treat refractory and early relapsed acute myeloid leukemia
2015
Role of deferiprone in chelation therapy for transfusional iron overload
2003
Antibody-Drug Conjugates in Cancer Therapy
2012
Cancer treatment and survivorship statistics, 2019
2019 Standout
Microbial degradation of complex carbohydrates in the gut
2012 Standout
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
2014
Natural product and natural product derived drugs in clinical trials
2014 Standout
Creating and Maintaining the Gastrointestinal Ecosystem: What We Know and Need To Know from Gnotobiology
1998
Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee
2004 Standout
The ecology of the microbiome: Networks, competition, and stability
2015 StandoutScience
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
2013
Acute myeloid leukaemia
2016
Bacteroides: the Good, the Bad, and the Nitty-Gritty
2007 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Applicability of a “Pick a Winner” trial design to acute myeloid leukemia
2011
Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients
1998
Works of Ann E. Hunter being referenced
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
2013
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
2012
Bone marrow transplantation: current situation, complications and prevention
1995
Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro
1994
Biological Features of Leukaemic Cells Associated with Autonomous Growth and Reduced Survival in Acute Myeloblastic Leukaemia
1995
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
2012
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
2007
The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial
2011
The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison
2010
AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial
2013
Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.
2009
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
2013